An industry funded study concludes the branded palmitoylethanolamide (PEA) ingredient ‘Levagen+’ is safe and effective in reducing the incidence and symptoms associated with upper respiratory tract infections (URTIs).
Palmitoylethanolamide (PEA) has shown to inhibit the COVID-19 virus in both in-silico and in-vitro settings, and positive findings from a clinical trial are expected to be published in Q3, says functional ingredient firm Gencor.
Palmitoylethanolamide (PEA) is a safer and more pervasive therapeutic alternative to cannabidiol, say the authors of the Gencor Pacific-commissioned review, ‘Palmitoylethanolamide: A Potential Alternative to Cannabidiol.’
A wrinkled type of ‘super pea,’ containing higher levels of gut-friendly ‘resistant starch,’ may prove beneficial to those at risk of type 2 diabetes, due to its ability to control blood sugar levels, a study thinks.
A Palmitoylethanolamide (PEA) supplement matches the efficacy of ibuprofen for reducing pain severity and duration of headaches creating an exciting opportunity within the eSports category, says Gencor.